Pharmaceutical

CORRECTION BY SOURCE: Notice of Extraordinary General Meeting in Promore Pharma AB (Publ)

Addition after section "Proposed AGENDA"STOCKHOLM, SE / ACCESSWIRE / November 29, 2023 / Promore Pharma (STO:PROMO)(FRA:8T0)The shareholders of Promore Pharma…

8 months ago

Notice of Extraordinary General Meeting in Promore Pharma AB (Publ)

STOCKHOLM, SE / ACCESSWIRE / November 29, 2023 / Promore Pharma (STO:PROMO)(FRA:8T0)The shareholders of Promore Pharma AB (publ), reg. no.…

8 months ago

GE HealthCare Highlights Commitment to Delivering Better Patient Experiences and Outcomes Through Deep Learning at RSNA 2023

GE HealthCare is proud to announce the addition of True Enhance DL to its Effortless Recon DL portfolioCHICAGO--(BUSINESS WIRE)--Through its…

8 months ago

BioHarvest Sciences Reports Q3 2023 Revenue Demonstrating Continued Growth Momentum

Q3 VINIA® revenues of USD 3.24M represent growth of 113% compared to Q3 2022 and 18% increase compared to Q2…

8 months ago

Clairvoyant Surpasses 50 Per Cent Randomization in its Phase 2b Psilocybin Therapy Trial for Alcohol Use Disorder

VANCOUVER, BC / ACCESSWIRE / November 29, 2023 / Clairvoyant Therapeutics Inc. (www.clairvoyantrx.com), the clinical-stage pharmaceutical company developing psilocybin therapy…

8 months ago

SELLAS Life Sciences Reaches Target Enrollment ex-China in Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia

Independent Data Monitoring Committee Scheduled to Meet This QuarterNEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group,…

8 months ago

Mangoceuticals Selects TRYBE Labs as its Nationwide Blood Collection and Testing Services Provider

TRYBE Labs to provide MangoRx customers with turnkey at-home blood collection services and solutions Dallas, Texas, Nov. 29, 2023 (GLOBE…

8 months ago

Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate

Primary endpoint met Demonstrated safety and reactogenicity of DYAI-100 recombinant proteinC1-cell produced antigen was both safe and well-toleratedNo Serious Adverse…

8 months ago

NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio With New RNA Sequences Promoting Healing and Regeneration

The PNN as new target for NurExone’s ExoTherapy platform. (A) Illustration of the extracellular Perineural network (PNN), highlighted in green.…

8 months ago

Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook

HANOVER, MD, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical…

8 months ago